Formulation Development
Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lipella Pharmaceuticals Inc. recently announced the receipt of US FDA Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a…
Limula Raises $6.8M to Democratise Access to Life-Saving Cell & Gene Therapies With Swiss-Made Manufacturing Platform
Over the past decade, several breakthrough Cell and Gene Therapy products have been approved in the US and Europe to turn stem cells and immune…
Molecure Receives Approval to Initiate Phase 2 Clinical Trial for the Treatment of Pulmonary Sarcoidosis
Molecure S.A. recently announced it has received national regulatory approvals from Denmark, France, Greece, Germany, and Norway to conduct a Phase 2 clinical trial for…
Sana Biotechnology Highlights Novel In Vivo Preclinical Data Showing Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-Based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice….
Premium Cell Culture Ingredients From Actylis
Download the Actylis Cell Culture Ingredients brochure to discover our product list or ask for a sample of a specific product…..
TFF Pharmaceuticals & Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
TFF Pharmaceuticals, Inc recently announced that, in collaboration with Cleveland Clinic, the company is advancing multiple multivalent universal influenza vaccines to protect against seasonal and…
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From EMA for Certepetide in Pancreatic Cancer
Lisata Therapeutics, Inc. recently announced it has reached agreement with the European Medicines Agency (EMA) on a Paediatric Investigation Plan (PIP) for Lisata’s lead investigational…
Coya Therapeutics Announces $5-Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation
Coya Therapeutics, Inc. recently announces the Alzheimer’s Drug Discovery Foundation (ADDF) has purchased 603,136 shares of the company’s common stock at a purchase price of…
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program Reduces the Important Inflammatory & Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently presented positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).…
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio, Inc. recently announced the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program…
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. recently announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau…
MoonLake Immunotherapeutics Starts Phase 3 VELA Program of the Nanobody Sonelokimab in Patients With Moderate-to-Severe Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced the first patients have been screened at a US trial site in its global Phase 3 clinical program, VELA, evaluating sonelokimab,…
Ocean Biomedical Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection & Treat Severe Disease
Ocean Biomedical recently announced that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted…
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal & Bulbar Muscular Atrophy
Avenue Therapeutics, Inc. recently announced the completion of the last patient’s final visit in the company’s Phase 1b/2a clinical trial of AJ201 for the treatment…
Veranova & Phorum.AI Partner to Deliver Generative AI Chemistry Optimization to the Pharmaceutical & Biotech Industry
Veranova and Phorum.AI recently announced they are collaborating on next-generation optimization of pharmaceutical manufacturing processes using artificial intelligence (AI). Building on years of research and…
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals, Inc. provided an update from the its ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant…
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene AG recently presented the company’s proprietary T cell receptor (TCR) discovery process to obtain optimal affinity 3S (sensitive, specific and safe) TCRs at the…
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Roquette Unlocks the Power of Flexibility With Launch of New Flex Softgel Capsule Shell System
Roquette recently announced the launch of its new LYCAGEL Flex hydroxypropyl pea starch premix for nutraceutical and pharmaceutical softgel capsules. Built on Roquette’s market-first LYCAGEL pea…
CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell…
